Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B

Aliment Pharmacol Ther. 2023 Nov;58(9):965-966. doi: 10.1111/apt.17712.

Authors

Rui Huang^{1

2

3}, Zhiyi Zhang³, Jian Wang^{1

2}, Shaoqiu Zhang¹, Chao Wu^{1

2

3}

Affiliations

¹ Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
² Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, China.
³ Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.

PMID: 37831536
DOI: 10.1111/apt.17712

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Aspirin / adverse effects
Carcinoma, Hepatocellular* / chemically induced
Carcinoma, Hepatocellular* / epidemiology
Hepatitis B virus
Hepatitis B*
Hepatitis B, Chronic* / complications
Hepatitis B, Chronic* / drug therapy
Humans
Liver Neoplasms* / chemically induced
Liver Neoplasms* / epidemiology

Substances

Aspirin